Venture Capital

Updated:

Murphree Venture Partners

Murphree Venture Partners is a venture capital and growth equity firm that invests in entrepreneurial enterprises in the southern United States.

Murphree Venture Partners logo

Murphree Venture Partners

Murphree Venture Partners is a venture capital and growth equity firm that invests in entrepreneurial enterprises in the southern United States. They have made 46 investments, including a Series F investment in Aerin Medical on May 04, 2022. The firm has 12 portfolio exits, with Pyxant Labs exiting on June 09, 2021.

General information

Firm type

Venture Capital

Year founded

1987

Location

Region

North America

Country

United States

City

Houston

Corporate office

Houston, TX, United States

Frequently asked questions

How does Murphree Venture Partners source its deals?

The firm leverages Dennis Murphree's deep operator network across the Sun Belt technology ecosystem, built over decades of founding and exiting software companies in Texas. Its Houston location provides access to deal flow that often escapes coastal venture attention, particularly from founders connected to the region's industrial, energy, and enterprise-software clusters. Murphree's track record of over 70 portfolio companies reinforces this proprietary sourcing channel.

What investment stages does Murphree Venture Partners target?

The firm invests from seed through growth stages, with a core focus on early-stage companies where operator involvement can materially influence outcomes. Seed and startup rounds represent the entry point for most positions, with follow-on reserves allocated to breakout portfolio companies. This stage-agnostic early approach mirrors the firm's thesis that Sun Belt founders need patient, operationally-informed capital from initial product-market fit through scaling.

Which sectors does Murphree Venture Partners explicitly avoid?

Murphree Venture Partners has not published formal sector exclusions. Based on its observed portfolio construction and the partners' expertise, the firm is unlikely to lead rounds in capital-intensive sectors like biotech and hard-science deep tech that fall outside its operator generalist model. The firm's preference tilts toward enterprise software and industrial technology where regional networks and operating experience can directly de-risk investments.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on venture capital firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More Houston Venture Capital profiles